Current Research Studies

A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma


What is the goal of the study?

The goal of this study to see if nivolumab + chemo-immunotherapy works better than chemo-immunotherapy alone. The study will be looking at the rate of remission, the rate of progression/relapse and the efficacy of these drugs.

Who can participate in the study?

This study may be a good for for children and young adults who are: 2 years or older Diagnosed with primary mediastinal B-cell lymphoma You can read more about the eligibility criteria for this study on Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for your child.

Study Team: